A PHASE 3, INTERNATIONAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF LINACLOTIDE ADMINISTERED ORALLY FOR 12 WEEKS TO PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C):